GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Cyclically Adjusted Revenue per Share

Beijing Strong Biotechnologies (SZSE:300406) Cyclically Adjusted Revenue per Share : ¥2.15 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beijing Strong Biotechnologies's adjusted revenue per share for the three months ended in Mar. 2024 was ¥0.686. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥2.15 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Beijing Strong Biotechnologies's average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-08), Beijing Strong Biotechnologies's current stock price is ¥17.31. Beijing Strong Biotechnologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥2.15. Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio of today is 8.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beijing Strong Biotechnologies was 11.64. The lowest was 7.88. And the median was 9.39.


Beijing Strong Biotechnologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Beijing Strong Biotechnologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Strong Biotechnologies Cyclically Adjusted Revenue per Share Chart

Beijing Strong Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.99 2.11

Beijing Strong Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 2.02 2.07 2.11 2.15

Competitive Comparison of Beijing Strong Biotechnologies's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio falls into.



Beijing Strong Biotechnologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beijing Strong Biotechnologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.686/115.2271*115.2271
=0.686

Current CPI (Mar. 2024) = 115.2271.

Beijing Strong Biotechnologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.608 98.200 0.713
201409 0.663 98.900 0.772
201412 0.617 99.000 0.718
201503 0.252 99.900 0.291
201506 0.566 99.500 0.655
201509 0.545 100.500 0.625
201512 0.646 100.600 0.740
201603 0.299 102.200 0.337
201606 0.291 101.400 0.331
201609 0.363 102.400 0.408
201612 0.352 102.600 0.395
201703 0.280 103.200 0.313
201706 0.293 103.100 0.327
201709 0.374 104.100 0.414
201712 0.482 104.500 0.531
201803 0.325 105.300 0.356
201806 0.360 104.900 0.395
201809 0.381 106.600 0.412
201812 0.373 106.500 0.404
201903 0.343 107.700 0.367
201906 0.356 107.700 0.381
201909 0.429 109.800 0.450
201912 0.549 111.200 0.569
202003 0.265 112.300 0.272
202006 0.277 110.400 0.289
202009 0.489 111.700 0.504
202012 0.542 111.500 0.560
202103 0.633 112.662 0.647
202106 0.757 111.769 0.780
202109 0.690 112.215 0.709
202112 0.643 113.108 0.655
202203 0.646 114.335 0.651
202206 0.579 114.558 0.582
202209 0.692 115.339 0.691
202212 0.686 115.116 0.687
202303 0.639 115.116 0.640
202306 0.746 114.558 0.750
202309 0.708 115.339 0.707
202312 0.829 114.781 0.832
202403 0.686 115.227 0.686

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Beijing Strong Biotechnologies  (SZSE:300406) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beijing Strong Biotechnologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.31/2.15
=8.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beijing Strong Biotechnologies was 11.64. The lowest was 7.88. And the median was 9.39.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beijing Strong Biotechnologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Strong Biotechnologies (SZSE:300406) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Executives
Shuang He Executives
Luo Ai Ping Director
Directors, executives
Liu Wei Executives
Zhou Ming Executives
Zhuang Xian Min Directors, executives
Zhang Yi Executives
Liu Xi Directors, executives
Sun Xiao Lin Director
Yu Jian Ping Executives

Beijing Strong Biotechnologies (SZSE:300406) Headlines

No Headlines